Financial Performance - The fully diluted earnings per share for 2022 is RMB 0.6102 per share, calculated based on the latest total share capital after the exercise of stock options[8]. - In 2022, the company achieved a total revenue of RMB 7.50 billion, representing a year-on-year increase of 14.37%[115]. - The total revenue for 2022 reached RMB 7,502,987,102.09, representing a year-on-year increase of 27.15% compared to RMB 5,465,656,107.15 in 2021[143]. - The net profit attributable to shareholders of the listed company reached RMB 411,193,683.53, reflecting a growth of 17.97% from RMB 348,548,495.99 in the previous year[177]. - The net profit after deducting non-recurring gains and losses was RMB 378,636,297.99, a significant increase of 29.97% from RMB 291,335,832.10 in 2021[177]. - The basic earnings per share rose to RMB 0.62, representing a 10.71% increase from RMB 0.56 in the previous year[177]. - The gross profit margin for the overall business was 14.37%, slightly up from 14.19% in the previous year[143]. - The revenue from the analgesic raw materials segment was RMB 3,171,564,382.95, showing a growth of 30.70% from RMB 2,198,020,297.84 in the previous year[143]. - The sales revenue of the top 10 strategic formulations grew by 30% year-on-year, with fish oil soft capsules exceeding RMB 10 million in sales[131]. - The international formulations and contract manufacturing sales increased by 88% year-on-year[131]. Shareholder Information - The top ten shareholders at the end of the reporting period include Hualu Holdings Group Co., Ltd. with 204,864,092 shares and Hong Kong Central Clearing Limited with 193,302,927 shares[12]. - The company proposed a dividend of RMB 0.20 per share for the year-end 2022, subject to approval at the annual general meeting[130]. - The company has a total of 1,284,620 shares held by key management personnel as of December 31, 2022, an increase from 826,270 shares in the previous year[39]. Management and Governance - The company has undergone changes in its board and management, with Xu Wenhui appointed as the general manager and executive director on September 19, 2022[28]. - The company’s board of directors held a total of 9 meetings in the year, with all independent directors attending[45]. - The board of directors has a clear responsibility to create value for shareholders and ensure effective management of the company[56]. - The company has established a performance evaluation and incentive mechanism for senior management[76]. - The company has implemented a board diversity policy to enhance the skills and perspectives of its members, focusing on various criteria including business experience and gender[88]. - The audit committee recommended the reappointment of the auditing firm for the year 2023 after reviewing the audited accounts and performance announcement for 2022[34]. Financial Reporting and Compliance - The company does not have any discrepancies between the financial indicators disclosed in the annual report and those in the quarterly and semi-annual reports[9]. - The company's financial statements for the year 2022 were prepared in accordance with the accounting policies and standards set by the Ministry of Finance of China, with no significant misstatements or omissions found[34]. - The company’s internal control over financial reporting is deemed effective, ensuring the reliability of financial statements[34]. - The company confirmed that all directors are entitled to seek independent professional advice at the company's expense, promoting informed decision-making[87]. - The internal control audit report was published on March 27, 2023, indicating ongoing compliance with regulatory requirements[81]. Employee and Training Initiatives - As of December 31, 2022, the total number of employees was 6,781, with 3,733 in production, 920 in sales, and 617 in engineering and technology[43]. - The company completed 65 training projects in 2022, training a total of 2,378 employees, enhancing their skills and capabilities[44]. - The company has established a comprehensive training system to improve employee capabilities and ensure effective management operations[44]. Research and Development - The company received 7 new product approvals for formulations and 5 consistency evaluation approvals in 2022, marking significant progress in drug innovation[106]. - The company has 28 drugs under research for consistency evaluation, with 8 products currently in the review queue at CDE[159]. - The company is accelerating the research and development of series of drugs including ibuprofen, high molecular drugs, and steroid hormones[136]. - Research and development expenses for 2022 were RMB 345,658,511.77, a slight increase of 1.26% from RMB 341,367,394.20 in 2021[146]. Cash Flow and Investments - The net cash inflow from operating activities increased significantly due to expanded sales scale and increased customer prepayments[149]. - The company’s cash and cash equivalents rose by RMB 244 million due to funds raised from a non-public offering and increased customer prepayments[153]. - The net cash flow from operating activities surged by 192.62% to RMB 758,240,601.50, compared to RMB 259,116,960.17 in 2021[177]. - The company reported a total initial investment cost of RMB 21,225,318.00 in securities, with a current book value of RMB 173,490,512.00[1]. Market and Competitive Landscape - The company is facing increased competition in the domestic pharmaceutical market due to intensified resource concentration and international economic challenges[134]. - The company plans to enhance its market competitiveness by implementing a "one product, one strategy" approach to stabilize the market and expand sales[135]. - The company aims to focus on product technology innovation and improve digital capabilities to drive future growth[110]. Audit and Oversight - The company has established an audit committee consisting of three independent non-executive directors, responsible for overseeing the fairness of financial reporting and internal controls[92]. - The audit committee met four times during the year to review financial statements and discuss audit matters, ensuring thorough oversight[92]. - The total audit fees for the company in 2022 amounted to RMB 1,177,358.48, compared to RMB 1,167,924.51 in 2021, reflecting a slight increase[91].

Financial Performance - The total revenue for 2022 was RMB 7,502,987,102.09, representing a 14.37% increase from RMB 6,560,077,586.40 in 2021[4]. - The net profit attributable to shareholders of the listed company was RMB 411,193,683.53, an increase of 17.97% compared to RMB 348,548,495.99 in the previous year[4]. - The operating cash flow net amount reached RMB 758,240,601.50, showing a significant increase of 192.62% from RMB 259,116,960.17 in 2021[4]. - The basic earnings per share increased to RMB 0.62, a rise of 10.71% from RMB 0.56 in the previous year[4]. - The diluted earnings per share also increased to RMB 0.61, reflecting an 8.93% growth compared to RMB 0.56 in 2021[4]. - The total comprehensive income for the year was RMB 413,373,076.38, up from RMB 313,908,790.25 in 2021, showing a growth of 31.69%[49]. - The operating profit for the year ended December 31, 2022, was RMB 476,706,533.91, compared to RMB 425,590,536.88 in 2021, indicating an increase of about 12.0%[54]. Assets and Liabilities - Total assets as of December 31, 2022, were RMB 8,265,131,332.13, up 12.73% from RMB 7,332,033,657.98 at the end of 2021[5]. - The total liabilities increased by 6.37% to RMB 3,915,226,169.32 from RMB 3,680,888,823.85 in the previous year[5]. - The net assets attributable to shareholders of the listed company rose by 18.99% to RMB 4,126,460,390.95 from RMB 3,467,941,567.45 in 2021[5]. - Current liabilities totaled RMB 3,158,485,539.10 as of December 31, 2022, compared to RMB 2,501,880,371.20 in 2021, indicating a significant increase of 26.29%[47]. - Long-term borrowings increased to RMB 545,655,801.48 in 2022 from RMB 346,196,870.64 in 2021, representing a growth of 57.67%[47]. Shareholder Information - As of December 31, 2022, the total number of shareholders was 107,300, including 38 H-share shareholders and 107,262 A-share shareholders[8]. - The proposed final dividend for the year 2022 is RMB 0.20 per share (before tax), subject to shareholder approval[12]. - The largest shareholder, China Hualu Holdings Group Co., Ltd., holds 30.59% of the shares, totaling 204,864,092 shares[10]. - The company emphasizes the importance of shareholder approval for the proposed dividend distribution[12]. - The proposed dividend for 2022 represents a 33.33% increase compared to the previous year's dividend[81]. Cash Flow and Investments - Cash and cash equivalents increased by 55.61% to RMB 1,158,741,565.90 compared to RMB 744,662,302.34 last year, primarily due to net proceeds from a non-public offering of A-shares amounting to RMB 244 million and an increase in customer prepayments[18][20]. - Net cash flow from operating activities reached RMB 758,240,601.50, a substantial increase of 192.62% compared to RMB 259,116,960.17 last year[23][24]. - The company achieved a fixed asset investment of RMB 720 million for the year, representing a year-on-year increase of 21%[30]. Research and Development - Research and development expenses increased by 1.26% to RMB 345,658,511.77 from RMB 341,367,394.20, reflecting ongoing investment in innovation[21]. - The company obtained 7 new product approvals for formulations and 4 for raw materials in 2022, including significant breakthroughs in drug innovation[29]. - The company plans to accelerate the development of new products, focusing on fish oil, hormones, and other specialty raw materials[33]. Market Performance - The sales revenue of the top 10 strategic formulations increased by 30% year-on-year, with the sales of fish oil soft capsules exceeding RMB 10 million[29]. - The international formulations and contract manufacturing sales saw an impressive year-on-year growth of 88%[29]. - The revenue from external transactions for the chemical raw materials segment was RMB 3,171,564,382.95 for the year ended December 31, 2022, compared to RMB 2,740,737,136.77 in 2021, marking an increase of approximately 15.7%[53]. Operational Efficiency - The company achieved a receivables turnover rate of 1,056.89% and an inventory turnover rate of 488.11% as of December 31, 2022[26]. - The company aims to enhance production efficiency and cost control through lean production and procurement management strategies[37]. - The company completed 30 technical quality projects and 21 energy transformation projects, saving RMB 20.9 million in raw material and energy consumption[30]. Compliance and Governance - The audit for the financial statements was conducted by Shinewing Certified Public Accountants, ensuring compliance with Chinese accounting standards[39]. - The company has established an audit committee to oversee financial reporting and internal controls, meeting four times during the year[44].

Group 1: Company Overview - Founded in 1943, Shandong Xinhua Pharmaceutical Co., Ltd. is the largest producer and exporter of antipyretic and analgesic drugs in Asia, and a significant manufacturer of cardiovascular, anti-infection, and central nervous system drugs [2] - The company produces over 300 varieties of products, including chemical raw materials, pharmaceutical preparations, intermediates, and chemical materials [3] Group 2: Production Capacity - Annual production capacity for chemical raw materials is 25,000 tons, making it the largest producer of drugs such as Anacin, Ibuprofen, Aspirin, and Caffeine globally [3] - The production capacity for pharmaceutical preparations includes 8 billion tablets, 300 million injections, and 200 million capsules annually [3] Group 3: Sales Performance - In the first half of 2014, raw material drug exports and domestic sales increased by 9% and 10% respectively, with significant sales growth for key products like Caffeine and Levodopa [3] - Sales of pharmaceutical preparations grew by 11.5% year-on-year, with new products such as Jiahualuo, Jiening, and Shutaide maintaining rapid sales growth [3] Group 4: Financial Performance - For the first half of 2014, the company achieved operating revenue of RMB 1,736,817 thousand, a 7.40% increase compared to the same period last year [3] - The operating profit was RMB 23,570 thousand, a significant turnaround from an operating loss of RMB 13,046 thousand in the previous year, attributed to technological advancements and cost reduction efforts [3]

Group 1: Financial Performance - In the first half of 2014, the company achieved operating revenue of RMB 1,736,817 thousand, an increase of 7.40% compared to the same period last year [2] - Operating profit for the first half of 2014 was RMB 23,570 thousand, a significant improvement from an operating loss of RMB 13,046 thousand in the previous year [2] - The increase in operating profit was attributed to technological advancements and energy-saving measures, leading to a significant reduction in raw material and energy consumption [2] Group 2: Product Overview - The company produces a total of 25,000 tons of chemical raw materials annually, making it the largest global producer of drugs such as Anacin, Ibuprofen, Aspirin, and Caffeine [3] - The production capacity for drug formulations includes 300 million tablets and 200 million capsules annually [3] - In the first half of the year, the export and domestic sales of raw materials increased by 9% and 10% respectively, with significant sales growth in key products like Caffeine and Levodopa [3] Group 3: Revenue Breakdown by Segment - Main business income and costs for different segments are as follows: - Raw Materials: Revenue of RMB 821,203 thousand, cost of RMB 679,855 thousand, with a gross margin of 17.21% [4] - Formulations: Revenue of RMB 353,593 thousand, cost of RMB 219,912 thousand, with a gross margin of 37.81% [4] - Commercial Circulation: Revenue of RMB 386,011 thousand, cost of RMB 365,480 thousand, with a gross margin of 5.32% [4] - Chemical Products and Others: Revenue of RMB 160,142 thousand, cost of RMB 133,376 thousand, with a gross margin of 16.71% [4] - Total main business income was RMB 1,720,949 thousand, with total costs of RMB 1,398,623 thousand, resulting in an overall gross margin of 18.73% [4]

Group 1: Company Overview - Shandong Xinhua Pharmaceutical Co., Ltd. is a key large-scale pharmaceutical enterprise in China, established in 1943, and is the largest production and export base for antipyretic and analgesic drugs in Asia [3] - The company is the world's largest producer of raw materials such as Acetaminophen, Ibuprofen, Aspirin, Caffeine, and Levodopa, with an annual production capacity of over 25,000 tons of chemical raw materials [3] - The tablet production capacity is 8 billion tablets per year, capsule production capacity is 200 million capsules per year, and injection production capacity is 300 million injections per year [3] Group 2: Financial Performance - The company has experienced poor performance in recent years, primarily due to increased environmental protection costs and depreciation from relocation [3] Group 3: Strategic Initiatives - The company is focusing on expanding its large dosage forms strategy, which includes increasing scale, variety, and sales volume [3] - The sales model for the company's formulations is primarily a combination of self-sales and agency sales [3] Group 4: Intermediate Products - The company's chemical intermediates are mainly produced and sold by its Shouguang facility, which has shown good production and sales performance this year [3] Group 5: Employee Compensation - The average salary of the company's employees is comparable to the average salary level of the local manufacturing industry [4]

Group 1: Company Overview - Xinhua Pharmaceutical's chairman and financial officer introduced the company's history, development process, and current structure, which includes raw materials, formulations, and intermediates [2] - The company emphasizes its development advantages and strategic focus areas [2] Group 2: Research and Development - In 2015, the company increased its R&D investment to enhance future growth, focusing on eight key areas: analgesics, cardiovascular, anti-diabetic, central nervous system, digestive system, anti-infection, anti-tumor, and health products [3] - The company employs various methods, including self-research, collaboration, and outsourcing, to accelerate technological innovation and expand its product range [3] Group 3: Sales and Product Strategy - In 2015, the sales revenue from self-produced formulations remained stable compared to 2014, despite adjustments in product structure [3] - The company is focusing on five key products: Jianing, Shutaide, Jiahelu, Aidite, and is actively promoting large-scale formulation and international development strategies [3] Group 4: Consistency Evaluation and Partnerships - The company has established a dedicated team to advance the consistency evaluation of its formulation products, aiming to gain a competitive edge in the future [3] - Current collaborations with the Zibo Health and Family Planning Commission, JD.com, and Xinhua Pharmacy are still in the preparatory stage [3]

证券代码： 000756 证券简称：新华制药 编号：2016-01 山东新华制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |--------------|------------------------------|--------------------------------------------------------------| | | | | | 投资者关系活 | √ | 特定对象调研 □分析师会议 | | 动类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称 | 西南证券：周平、王彦、乔学敏 | | | 及人员姓名 | 民生加银基金：蒯学章 | | | 时间 | 2016 年 5 月 5 | 日 | | 地点 | 公司会议室 | | | 上市公司接待 | 董事会秘书：曹长求 | | | 人员姓名 | | | | 投资者关系活 | 1、 | 介绍公司基本情况 | | 动主要内容介 | | 公司董事会秘书简要介绍了一下公司发展的历史，介绍了公司园区布 | ...

Group 1: Company Overview - The company is Shandong Xinhua Pharmaceutical Co., Ltd., with stock code 000756 and abbreviation Xinhua Pharmaceutical [1] - The investor relations activity took place on May 17, 2016, in the company meeting room [2] Group 2: Sales and Product Development - In 2015, the sales revenue of self-produced formulations remained stable despite product structure adjustments [2][3] - The company focuses on five key products: Jianing, Shutaide, and Jiahualuo, among others, aiming to cultivate multiple products with sales exceeding 100 million [3] Group 3: Strategic Initiatives - The company is advancing its large formulation development strategy and internationalization efforts [3] - Key strategies include strengthening the marketing team, enhancing international cooperation through OEM production, and cultivating quality formulation varieties [3] Group 4: Financial Performance - The profit situation of chemical intermediates in 2015 was favorable due to cost savings [3] - The gross profit margin of raw materials in 2015 was higher than in 2014, attributed to the implementation of a bidding procurement system and cost reduction measures [3]

证券代码： 000756 证券简称：新华制药 编号：2020-02 山东新华制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------|-------------------------|----------------------------------------------------------------------------| | | | | | 投资者关系活 | □ | 特定对象调研 √分析师会议 | | 动类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称 | | 光大证券林小伟、广发基金王瑞冬、长安基金肖洁、东海基金赵子淇、平 | | 及人员姓名 | 娇及刘树坤等多家单位 | 安资产万淑珊、中欧基金贾雅希、中金基金潮礼君及兰兰、南方基金王峥 90 人 | | | | | | 时间 | 2020 年 3 月 24 | 日 | | 地点 | 电话、网络 | | | 上市公司接待 | | 董事长张代铭、副总经理贺同庆、财务负责人侯 ...

Group 1: Company Overview - Founded in 1943, Xinhua Pharmaceutical has a 77-year development history and is a key global producer and exporter of antipyretic and analgesic drugs, with total assets exceeding 6 billion RMB and over 6,000 employees [2][3]. - The company operates 13 subsidiaries and five major industrial parks, establishing a complete industrial chain from intermediates to high-quality pharmaceuticals [3][4]. Group 2: Competitive Advantages - Xinhua's "Xinhua" trademark, registered in 1950, is a well-known brand in China, with 21 FDA registrations, 11 EU EDQM numbers, and 3 ANDA numbers, ensuring product quality meets the highest global standards [3]. - The company has a production capacity of 35,000 tons for chemical raw materials annually, with leading market shares in six main raw materials, including ibuprofen and paracetamol [4][5]. Group 3: Research and Development - Xinhua is recognized as a national high-tech enterprise, with 3 new class I drugs and 10 class II drugs developed, holding 102 new drug production numbers and 215 authorized patents [5][6]. - R&D investment increased by 26.93% in 2019, accounting for 4.02% of revenue, indicating a commitment to innovation and product competitiveness [7][8]. Group 4: Market Position and Internationalization - The company exports nearly 300 million USD annually, with products reaching over 50 countries and regions, establishing long-term strategic partnerships with major multinational corporations [5][6]. - Xinhua is among the top five raw material drug exporters and top ten formulation exporters in China, actively pursuing international cooperation projects [5][6]. Group 5: Financial Performance and Future Outlook - In 2019, the net value of fixed assets was 2.806 billion RMB, with annual depreciation of 332 million RMB, indicating a focus on sustainable development [6][10]. - The company aims to enhance its formulation market development over the next five years, targeting significant sales growth and improved profitability [8][9].